Mechelen, Belgium;
25 January 2008 – Galapagos NV (Euronext & LSE:
GLPG) announced today achievement of a milestone under its
alliance agreement in rheumatoid arthritis with Janssen
Pharmaceutica NV (‘Janssen’). The milestone
triggered a cash payment of €3.4 million to Galapagos.
On 24 October 2007, Galapagos
announced an alliance agreement with Janssen providing it
with option rights to acquire worldwide, commercial licenses
to novel small-molecules from up to 12 of Galapagos’
internal programs involving rheumatoid arthritis (RA) therapeutic
targets. The milestone announced today was due to the achievement
of a milestone with respect to the GT146 program.
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam,
GLPGA; London AiM: GLPG) is a drug discovery company with
pre-clinical programs in bone and joint diseases and cachexia.
Its division BioFocus DPI offers a full suite of target-to-drug
discovery products and services to pharmaceutical and biotech
companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates. BioFocus DPI also provides adenoviral reagents
for rapid identification and validation of novel drug targets,
compound libraries for drug screening as well as chemogenomics
and ADMET database products to select targets and compounds.
Galapagos currently employs 460 people and operates facilities
in seven countries, with global headquarters in Mechelen,
Belgium. More information about Galapagos and BioFocus DPI
can be found at www.glpg.com
and www.biofocusdpi.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements,
including, without limitation, statements containing the
words “believes,” “anticipates,”
“expects,” “intends,” “plans,”
“seeks,” “estimates,” “may,”
“will,” “could,” “stands to,”
and “continues,” as well as similar expressions.
Such forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause
the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied
by such forward-looking statements. Given these uncertainties,
the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document.
Nothing in this disclaimer is intended to nor does it affect
the obligations and responsibilities of Galapagos pursuant
to the rules of the exchanges on which Galapagos' shares
are admitted for trading, including the AIM Rules for Companies.
